There are 2949 resources available
LBA26 - Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease
Presenter: Ramaprasad Srinivasan
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
703MO - An integrated study of spatial dynamics and genomic alterations in renal cell carcinoma evolution
Presenter: Yue Zhao
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA27 - Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy
Presenter: Begona Perez Valderrama
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1673MO - The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management
Presenter: Astrid LIÈVRE
Session: Mini Oral - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast
812MO - Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
Presenter: Nicoletta Colombo
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
1623MO - Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Presenter: Filip Janku
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1624MO - Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS)
Presenter: Javier Martin Broto
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA62 - Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
Presenter: Helena Yu
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1421MO - Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma
Presenter: Salah-Eddin Al-Batran
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
1422MO - Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
Presenter: Kensei Yamaguchi
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast